Vor Bio
Vor is a biotech company focused on addressing autoimmune diseases at their root causes through innovative therapies like telitacicept. The company offers opportunities for impact, growth, and a collaborative culture. They are working on advancing treatments with potential across multiple autoimmune conditions.
Vor Bio is a clinical-stage cell and genome engineering company developing novel hematopoietic stem cell-based therapies for cancer. The company is focused on transforming the treatment of hematological malignancies through engineered stem cell transplantation and targeted therapeutics.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Vor Bio.
Vor, with new CEO, changes course to target autoimmune disease
Jun 26, 2025
Senior Director, Clinical Operations
Jade Biosciences
Clinical Research Associate (in-house)
Artiva Biotherapeutics
Director, Investor Relations and Corporate Communications
Zenas BioPharma
Associate Clinical Project Manager
Zenas BioPharma
IT Support Specialist (Contractor)
Artiva Biotherapeutics
Director, Regulatory Operations
Zenas BioPharma